Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Mostrar otras versiones (1)

BACKGROUND: Although trastuzumab and other HER2-targeted therapies have significantly improved survival in patients with HER2 overexpressed or amplified (HER2+) breast cancer, a significant proportion of patients do not respond or eventually develop clinical resistance. Strategies to reverse trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuying, Xie, Shelly M., Liu, Wenbin, Gagea, Mihai, Hanker, Ariella B., Nguyen, Nguyen, Raghavendra, Akshara Singareeka, Yang-Kolodji, Gloria, Chu, Fuliang, Neelapu, Sattva S., Hanash, Samir, Zimmermann, Johann, Arteaga, Carlos L., Tripathy, Debasish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949251/
https://www.ncbi.nlm.nih.gov/pubmed/36824840
http://dx.doi.org/10.21203/rs.3.rs-2388864/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949251/
https://www.ncbi.nlm.nih.gov/pubmed/36824840
http://dx.doi.org/10.21203/rs.3.rs-2388864/v1

Ejemplares similares